A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Condition:   Crohn's Disease Intervention:   Drug: Mirikizumab Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Condition:   Crohn Disease Interventions:   Diagnostic Test: PillCamTM Crohn's capsule;   Diagnostic Test: Magnetic resonance enterography;   Procedure: Ileo-colonoscopy Sponsors:   South Tyneside and Sunderland NHS Foundation Trust;   County Durham and Darlington NHS Foundation Trust;   Sheffield Teaching Hospitals NHS Foundation Trust;   Newcastle University;   Durham University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Crohn Disease Interventions:   Other: High-impact exercise intervention;   Other: Acute response to high-impact exercise Sponsors:   NHS Greater Glasgow and Clyde;   University of Glasgow Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Inflammatory bowel disease (IBD) is a chronic disease that is associated with aspects of brain anatomy and activity. In this preliminary MRI study, we investigated differences in brain structure and in functional connectivity (FC) of brain regions in 35 participants with Crohn's disease (CD) and 21 healthy controls (HC). Voxel-based morphometry (VBM) analysis was performed to contrast CD and HC structural images. Region of interest (ROI) analyses were run to assess FC for resting-state network nodes. Independent component analysis (ICA) identified whole brain differences in FC associated with resting-state networks. Though...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Condition:   Crohn Disease Intervention:   Drug: Infliximab Sponsor:   Second Affiliated Hospital of Wenzhou Medical University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Crohn's Disease (CD) Intervention:   Other: Time Restricted Feeding Sponsors:   Weill Medical College of Cornell University;   The Kenneth Rainin Foundation Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Crohn Disease Intervention:   Drug: Infliximab Sponsor:   Second Affiliated Hospital of Wenzhou Medical University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: our results support ABP 501 as an effective and well-tolerated drug, with a good interchangeability with its originator for the treatment of Crohn's disease. PMID: 32054272 [PubMed - as supplied by publisher]
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research
Conclusion: Two-thirds of the patients demonstrated stable clinical benefit from maintenance IFX. The results show steroid-sparing efficacy as well as improved quality of life and reduced need for surgery. PMID: 32052663 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
Recent evidence points to a plausible role of diet and the microbiome in the pathogenesis of both Crohn ’s disease (CD) and Ulcerative Colitis (UC). Dietary therapies based on exclusion of table foods and replacement with nutritional formulas and/or a combination of nutritional formulas and specific table foods may induce remission in CD. In UC, specific dietary components have also been associated with flare of disease. While evidence of varying quality has identified potential harmful or beneficial dietary components, physicians and patients at the present time do not have guidance as to which foods are safe, may b...
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
We reported the event rates for the number of patients hospitalized, in a follow-up survey of 20,987 patient-years, and for the patients who underwent surgery in a follow-up of 5061 patient-years, with ORs of 0.233 with 95%CI 0.227-0.239, and 0.124 with 95%CI 0.114-0.135 (P
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
More News: Crohn's Disease | Inflammatory Bowel Disease | Research | Study